Cell culture in immune cell therapies: do more with less
Cell & Gene Therapy Insights 2023; 9(4), 473–486
Published: 29 May
Anastasiya Smith, Josh Ludwig, David Hermanson
In this expert roundtable, David McCall, Senior Editor, BioInsights, speaks to (pictured left to right) Anastasiya Smith, Senior Director, R&D, Marker Therapeutics, Inc, Josh Ludwig, Global Director, Commercial Operations, ScaleReady, & David Hermanson, Senior Manager of R&D Applications, Cell and Gene Therapy, Bio-Techne. The panel discusses the importance of cytokine levels and the effects on phenotype, in addition to how to reduce complexity and cost from early research through commercial scale-up in a closed system.